On September 25, 2019 Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female-specific oncology products in the precision medicine metastatic breast cancer arena, reported that it will present a poster at the 2019 Annual Meeting of the North American Menopause Society (NAMS) on oncologists’ perception of sexual intimacy concerns by patients with metastatic breast cancer (Press release, Sermonix Pharmaceuticals, SEP 25, 2019, View Source [SID1234539775]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentation of the poster "Oncologists’ Perception of Sexual Intimacy Issues in Metastatic Breast Cancer: An Opportunity to Address Patientsʼ Concerns and Improve Quality of Life" will be held Sept. 26 from 6 p.m. to 7 p.m. at the Hyatt Regency in Chicago.
"This survey’s results confirm the need for oncology practitioner medical education programs that increase awareness, knowledge, and communication tools, providing patients undergoing treatment for metastatic breast cancer with options and resources that may improve their ability to be intimate with partners as they traverse their challenging journey," said presenting author Dr. Lisa Larkin, M.D., founder and chief executive officer of Ms. Medicine. "I look forward to detailing the survey’s findings at the NAMS Annual Meeting."
The study follows a University of Michigan patient-based survey that found sexual concerns were very common for women undergoing treatment for metastatic breast cancer and that these concerns often were overlooked by their oncologists.1
"Those of us with metastatic breast cancer know our lives will be shortened because of this disease, but our sex lives shouldn’t suffer an even earlier death," said Dr. Kelly Shanahan, a patient advocate and OB-GYN who in 2013 herself was diagnosed with metastatic breast cancer. "Sexual side effects of our treatments are real impediments to our quality of life, and the quality of life of our partners."